// App-Quantinova.ai

2026 : Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients

Researchers

Presenter

  • Giovanni Fernando Torelli

Principal Investigators

  • Nadia Peragine

  • Sara Raponi

  • Paola Mariglia

  • Simona Pauselli

  • Maria Stefania De Propris

  • Antonella Vitale

  • Anna Guarini

  • Robin Foa

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 56

  • Fc gamma RIIIa

  • Glomeruloid microvascular proliferation

  • Interleukin-15

  • Interleukin-2

  • NKp46

Drug/Treatment

  • IL-15

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved